1. Home
  2. FC vs SGMT Comparison

FC vs SGMT Comparison

Compare FC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Covey Company

FC

Franklin Covey Company

HOLD

Current Price

$15.22

Market Cap

157.5M

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$4.66

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FC
SGMT
Founded
1983
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
157.5M
169.4M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
FC
SGMT
Price
$15.22
$4.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$26.00
$26.38
AVG Volume (30 Days)
169.1K
321.0K
Earning Date
04-01-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$267,067,000.00
$2,000,000.00
Revenue This Year
$3.02
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.16
$1.73
52 Week High
$28.39
$11.41

Technical Indicators

Market Signals
Indicator
FC
SGMT
Relative Strength Index (RSI) 62.50 38.78
Support Level $14.04 N/A
Resistance Level $20.33 $6.62
Average True Range (ATR) 0.71 0.30
MACD 0.62 -0.03
Stochastic Oscillator 87.40 7.35

Price Performance

Historical Comparison
FC
SGMT

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: